1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study

Primary Author / Presenter(s)

CC

Catherine C. Coombs, MD

University of California Irvine
Irvine, California, United States

Co-Author(s)

Jennifer A. Woyach, MD

Professor of Medicine
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Jennifer R. Brown, MD, PhD

Director, CLL Center, and Institute Physician; Worthington Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts, United States
Paolo Ghia, MD, PhD

Professor of Medical Oncology
Università Vita Salute and IRCCS Ospedale San Raffaele
Milano, Lombardia, Italy
Lindsey E. Roeker, MD

Senior Associate Consultant
Division of Hematology, Mayo Clinic
Rochester, Minnesota, United States
Krish Patel, MD

Director Lymphoma Program
Swedish Cancer Institute
Seattle, Washington, United States
TE

Toby A. A. Eyre, MRCP, FRCPath, MD

Consultant Haematologist
Churchill Hospital, Oxford University
Oxford, England, United Kingdom
CT

Constantine S. Tam, MD, MBBS

Consultant Haematologist
Alfred Hospital and Monash University
Melbourne, Victoria, Australia
JS

John Seymour, MBBS, PhD, FRACP

Director, Department of Haematology
Peter MacCallum Cancer Centre & Royal Melbourne Hospital
Melbourne, Victoria, Australia
NS

Nirav N. Shah, MD

Medical College of Wisconsin
Milwaukee, Wisconsin, United States
IF

Ian W. Flinn, MD, PhD

Tennessee Oncology/OneOncology
Nashville, Tennessee, United States
CC

Chan Y. Y. Cheah, MD

Haematologist
Sir Charles Gairdner Hospital; Medical School, University of Western Australia; Linear Clinical Research
Nedlands, Australia
SM

Shuo Ma, MD, PhD

Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
JR

Joanna Rhodes, MD

Rutgers Cancer Institute of New Jersey, New Jersey, United States
KI

Koji Izutsu, MD, PhD

Director
Department of Hematology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Wojciech Jurczak, MD, PhD

Consultant, Head of Dpt of Lymphoid Malignancies
Maria Skłodowska-Curie National Research Institute of Oncology
Kraków, Malopolskie, Poland
WW

William G. Wierda, MD, PhD

Professor of Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
LH

Lisa M Hess, PhD

Eli Lilly and Company
Indianapolis, Indiana, United States
NB

Naleen Raj Bhandari, MS, PhD

Eli Lilly and Company, Indianapolis, IN, USA
Indianapolis, Indiana, United States
AL

Angely Loubert, MD

Modus Outcomes, Lyon, France
Lyon, Auvergne, France
PA

Paolo Abada, MD

Eli Lilly and Company
Indianapolis, Indiana, United States
NL

Nicole Lamanna, MD

Associate Professor
Columbia University Medical Center
New York, New York, United States